专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US06462024B1 Use of inhibitors of the sodium-hydrogen exchanger for the production of a medicament for decreasing undesired effects of substrates of the heart 失效
标题翻译：使用钠氢交换器的抑制剂来制备用于减少心脏底物的不希望的作用的药物
公开(公告)号：US06462024B1
公开(公告)日：2002-10-08
申请号：US09614122
申请日：2000-07-11
申请人： Hans Jochen Lang , Hartmut Rütten , Holger Heitsch , Wolfgang Linz , Bernward Schölkens
发明人： Hans Jochen Lang , Hartmut Rütten , Holger Heitsch , Wolfgang Linz , Bernward Schölkens
IPC分类号： A61K3170
CPC分类号： A61K31/00 , A61K31/165 , A61K31/166 , A61K31/70 , A61K45/06
摘要： Inhibitors of the sodium-hydrogen exchanger are used for the production of a medicament for decreasing the undesired effects in human and in veterinary medicine which originate from substances which cause damage to the heart when administered acutely or chronically.
摘要翻译：钠氢交换剂的抑制剂用于生产用于减少人类和兽医学中不期望的作用的药物，其起源于当急性或慢性施用时引起心脏损伤的物质。

2. 发明授权

US06593352B2 Substituted anthranilic acids, their use as a medicament or diagnostic, and medicament comprising them, and a pharmaceutical combination preparation containing a sodium/hydrogen exchange (NHE) blocker 失效
标题翻译：取代的邻氨基苯甲酸，它们作为药物或诊断剂的用途，以及包含它们的药物和含有钠/氢交换（NHE）阻断剂的药物组合制剂
公开(公告)号：US06593352B2
公开(公告)日：2003-07-15
申请号：US10003282
申请日：2001-12-06
申请人： Andreas Weichert , Hans-Willi Jansen , Heinz-Werner Kleemann , Hans-Jochen Lang , Hartmut Rütten
发明人： Andreas Weichert , Hans-Willi Jansen , Heinz-Werner Kleemann , Hans-Jochen Lang , Hartmut Rütten
IPC分类号： C07C31139
CPC分类号： C07D213/42 , C07C311/39 , C07D307/52 , C07D333/20
摘要： Substituted anthranilic acids of the formula I their use as a medicament or diagnostic, and medicament comprising them, and a pharmaceutical combination preparation containing a sodium/hydrogen exchange (NHE) blocker.
摘要翻译：式Itheir的取代的邻氨基苯甲酸用作药物或诊断剂，以及包含它们的药物，以及含有钠/氢交换（NHE）阻断剂的药物组合制剂。

3. 发明授权

US06680333B2 Imidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them 有权
标题翻译：咪唑烷衍生物，其制备方法，用途及药物制剂
公开(公告)号：US06680333B2
公开(公告)日：2004-01-20
申请号：US10092901
申请日：2002-03-08
申请人： Volkmar Wehner , Horst Blum , Hartmut Rütten , Hans Ulrich Stilz
发明人： Volkmar Wehner , Horst Blum , Hartmut Rütten , Hans Ulrich Stilz
IPC分类号： A61K3144
CPC分类号： C07D401/12 , C07D233/76 , C07D233/78
摘要： The present invention relates to novel imidazolidine derivatives of formula I, wherein A, E, Z, R1, R2, R3, R4 and R5 have the meanings indicated in the claims. The compounds of formula I are valuable pharmaceutical active compounds which are suitable, for example, for the treatment of inflammatory diseases, including rheumatoid arthritis, or allergic diseases. The compounds of formula I are inhibitors of the adhesion and migration of leukocytes and/or antagonists of the adhesion receptor VLA-4 belonging to the integrins group. They are generally suitable for the treatment of diseases which are caused by an undesired extent of leukocyte adhesion and/or leukocyte migration or are associated therewith or in which cell-cell or cell-matrix interactions which are based on the interactions of VLA-4 receptors with their ligands play a role. The invention furthermore relates to processes for the preparation of the compounds of formula I, their use and pharmaceutical preparations which contain compounds of formula I.
摘要翻译：本发明涉及式I的新型咪唑烷衍生物，其中A，E，Z，R 1，R 2，R 3，R 4和R 5具有权利要求书中所示的含义。式I化合物是有价值的药物活性化合物，其适用于例如用于治疗炎性疾病，包括类风湿性关节炎或过敏性疾病。式I化合物是属于整联蛋白组的粘附受体VLA-4的白细胞和/或拮抗剂的粘附和迁移的抑制剂。它们通常适用于治疗由白细胞粘附和/或白细胞迁移的不期望程度或与之相关的疾病或其中基于VLA-4受体的相互作用的细胞 - 细胞或细胞 - 基质相互作用引起的疾病其配体发挥作用。本发明还涉及制备式I化合物的方法，其用途和含有式I化合物的药物制剂。

4. 发明授权

US06962937B2 Imidazolidine derivatives, their preparation and their use 有权
标题翻译：咪唑烷衍生物，其制备及其应用
公开(公告)号：US06962937B2
公开(公告)日：2005-11-08
申请号：US10208182
申请日：2002-07-31
申请人： Volkmar Wehner , Stefanie Flohr , Horst Blum , Hartmut Rütten , Hans Ulrich Stilz
发明人： Volkmar Wehner , Stefanie Flohr , Horst Blum , Hartmut Rütten , Hans Ulrich Stilz
IPC分类号： A61K31/4166 , A61K31/4174 , A61P1/04 , A61P3/10 , A61P7/00 , A61P9/00 , A61P9/10 , A61P11/06 , A61P19/02 , A61P25/00 , A61P29/00 , A61P31/04 , A61P33/06 , A61P35/00 , A61P37/02 , A61P37/04 , A61P37/08 , A61P43/00 , C07D233/70 , C07D233/72 , C07D233/74 , C07D233/86 , C07D405/12 , C07D233/02
CPC分类号： C07D405/12 , C07D233/74
摘要： The present invention relates to novel imidazolidine derivatives of the formula I, in which B, E, W, Y, R, R2, R3, R30, e and h have the meanings given herein. The compounds of the formula I are valuable pharmaceutically active compounds which are suitable, for example, for treating inflammatory diseases, for example, rheumatoid arthritis, or allergic diseases. The compounds of the formula I are inhibitors of the adhesion and migration of leukocytes and/or antagonists of the adhesion receptor VLA-4, which belongs to the integrin group. They are generally suitable for treating diseases which are caused by, or associated with, an undesirable degree of leukocyte adhesion and/or leukocyte migration or in which cell-cell or cell-matrix interactions, which are based on the interactions of VLA-4 receptors with their ligands, play a role. The invention furthermore relates to processes for preparing the compounds of the formula I, to their use and to pharmaceutical preparations which comprise compounds of the formula I.
摘要翻译：本发明涉及式I的新型咪唑烷衍生物，其中B，E，W，Y，R，R 2，R 3，R 30 e和h具有本文给出的含义。式I化合物是有价值的药物活性化合物，其适用于例如治疗炎性疾病，例如类风湿性关节炎或过敏性疾病。式I的化合物是属于整联蛋白基团的粘附受体VLA-4的白细胞和/或拮抗剂的粘附和迁移的抑制剂。它们通常适用于治疗由不利程度的白细胞粘附和/或白细胞迁移引起的或与之相关的疾病，或其中基于VLA-4受体的相互作用的细胞 - 细胞或细胞 - 基质相互作用与他们的配体，发挥作用。本发明还涉及制备式I化合物及其用途和药物制剂的方法，所述药物制剂包含式I化合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式